ABOS Acumen Pharmaceuticals, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1576885 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY22.0%
TTM EPS YoY29.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-162.7%
ROA-91.3%
ROIC (approx.)-195.6%
Asset turnover—
Leverage & solvency
Liabilities / assets59.6%
Debt / equity0.76x
Current ratio1.89x
Interest coverage-24.65x
Cash quality & payout
Operating cash flow / net income0.85x
Accruals ratio-14.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $104.89M | $93.80M | $42.32M | $32.36M | $12.30M |
| SG&A expense | $18.95M | $20.22M | $18.82M | $12.88M | $7.28M |
| Operating income | -$123.83M | -$114.02M | -$61.14M | -$45.24M | -$19.58M |
| Interest expense | $4.22M | $4.07M | $581,000 | $0 | — |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$121.33M | -$102.33M | -$52.37M | -$42.86M | -$100.61M |
| EBITDA | -$123.77M | -$113.95M | -$61.08M | -$45.20M | -$19.58M |
| EPS (basic) | -2.00 | -1.71 | -1.08 | -1.06 | -5.02 |
| EPS (diluted) | -2.00 | -1.71 | -1.08 | -1.06 | -5.02 |
| Weighted avg. shares (diluted) | 60.56M | 60.01M | 48.61M | 40.60M | 20.06M |
| Balance sheet | |||||
| Cash & equivalents | $53.99M | $35.86M | $67.12M | $130.10M | $122.16M |
| Short-term investments | $62.88M | $135.93M | $176.64M | $47.50M | $72.08M |
| Current assets | $122.25M | $178.31M | $246.62M | $180.33M | $198.66M |
| PP&E, net | $103,000 | $73,000 | $122,000 | $165,000 | $36,000 |
| Total assets | $122.83M | $238.99M | $310.12M | $196.59M | $230.33M |
| Current liabilities | $30.01M | $27.61M | $12.97M | $7.81M | $5.15M |
| Short-term debt | $8.77M | $0 | — | — | — |
| Long-term debt | $22.40M | $29.42M | $29.90M | $0 | — |
| Total debt | $31.16M | $29.42M | $29.90M | $0 | — |
| Total liabilities | $52.40M | $57.18M | $43.15M | $7.81M | $5.15M |
| Shareholders' equity | $70.43M | $181.82M | $266.97M | $188.78M | $225.18M |
| Net debt | -$22.83M | -$6.44M | -$37.22M | -$130.10M | — |
| Shares outstanding | 60.58M | 60.09M | 57.91M | 41.03M | 40.47M |
| Cash flow statement | |||||
| Operating cash flow | -$115.54M | -$86.22M | -$43.06M | -$35.15M | -$17.96M |
| Capital expenditure | $88,000 | $16,000 | $21,000 | $161,000 | $40,000 |
| Free cash flow | -$115.63M | -$86.23M | -$43.09M | -$35.31M | -$18.00M |
| Investing cash flow | $133.93M | $48.03M | -$171.67M | $39.19M | -$104.12M |
| Financing cash flow | -$34,000 | $6.93M | $151.75M | $3.91M | $200.47M |
| Depreciation & amortization | $58,000 | $63,000 | $61,000 | $32,000 | $4,000 |
| Stock-based compensation | $9.85M | $9.63M | $6.14M | $3.06M | $922,000 |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-19 06:28.